A Phase Ia/Ib, Open Label, Multicenter, Dose-escalation Study of BI 907828 in Patients With Advanced or Metastatic Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 29 Jan 2019
At a glance
- Drugs BI 907828 (Primary)
- Indications Brain metastases; Glioblastoma; Non-small cell lung cancer; Soft tissue sarcoma; Solid tumours; Urogenital cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Boehringer Ingelheim
- 22 Jan 2019 Planned number of patients changed from 200 to 102.
- 06 Jun 2018 Planned End Date changed from 24 Apr 2023 to 13 Jun 2023.
- 06 Jun 2018 Status changed from not yet recruiting to recruiting.